Research programme: musculoskeletal disorders stem cell therapy - OrthoCyte

Drug Profile

Research programme: musculoskeletal disorders stem cell therapy - OrthoCyte

Alternative Names: OTX-CP03; OTX-CP07

Latest Information Update: 17 Oct 2015

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator OrthoCyte
  • Class Stem cell therapies
  • Mechanism of Action Cartilage replacements; Cell replacements; Tissue replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Musculoskeletal disorders; Osteoarthritis

Most Recent Events

  • 30 Sep 2015 OrthoCyte and Heraeus Medical enter into an exclusive and worldwide licensing agreement for the development of bone grafting therapies
  • 10 Aug 2015 BioTime has a patent protection for the manufacturing method of cartilage cells
  • 22 May 2015 Preclinical development is ongoing in USA (BioTime, Form 10-K, March 2015)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top